Dishman Pharmaceuticals | Latest & Breaking News on Dishman Pharmaceuticals | Photos, Videos, Breaking Stories and Articles on Dishman Pharmaceuticals

Buy Dishman Pharma; target of Rs 198: Karvy

Karvy is bullish on Dishman Pharma has recommended buy rating on the stock with a target price of Rs 198 in its research report dated August 05, 2016.

Hold GlaxoSmithKline Pharma: Ambareesh Baliga

Ambareesh Baliga of Edelweiss Financial Services is of the view that one may hold GlaxoSmithKline Pharmaceuticals as the stock may head higher.

Buy CEAT, Dishman Pharmaceuticals: Angel Broking

Brokerage house Angel Broking is bullish on CEAT, Dishman Pharmaceuticals and has recommended buy rating on both the stocks with a target price of Rs 170 and Rs 132 respectively in its research reports dated August 2, 2013.

Prefer L&T, BHEL to GMR Infra: Sukhani

Sudarshan Sukhani, s2analytics.com is of the view that one should exit GMR Infrastructure and enter Larsen and Toubro, BHEL. One can buy Dishman Pharmaceuticals at current level but stock will move only if the Nifty moves up.

Buy Exide Industries, says Sudarshan Sukhani

Buy Exide Industries, says Sudarshan Sukhani of s2analytics.com. It is on the verge of a new breakout on the upside.

Buy Reliance Industries around Rs 750-755: Baliga

Ambareesh Baliga, Market Analyst advice traders to buy Reliance Industries around Rs 750-755.

Dishman Pharma expects 25% growth in FY13

Dishman Pharmaceuticals posted a 13.24% topline growth in the fourth quarter of FY12 and reported a consolidated net profit of Rs 312.94 million for the quarter ended 31 March, 2012, up 37.30% from Rs 227.92 million in the corresponding quarter last year.

Buy Dishman Pharmaceuticals; target Rs 68: Angel Broking

Angel Broking is bullish on Dishman Pharmaceuticals and has recommended buy rating on the stock with a target price of Rs 68 in its November 16, 2011 research report.

Dishman Pharma eyes over 15% topline growth going forward

Managing director of Dishman Pharmaceuticals, JR Vyas expects the topline growth to be 15% or even more going forward. He also added that the bottomline will grow in the second half too.

Dishman's Swiss subsidiary to get nod for high potency drug

Dishman Pharmaceuticals and Chemicals'(DPCLs) today said that its Switzerland-based wholly owned subsidiary -Carbogen Amcis AG- has successfully completed USFDA Pre Approval Inspection (PAI) for a new high potency drug for a US multinational.

Hold Dishman Pharma; target Rs 100: KRChoksey

KRChoksey has maintained hold rating on Dishman Pharmaceuticals (DPL) with a target price of Rs 100 in its July 29, 2011 research report.

Pharma firms want tax cuts, R&D sops boost

Drugmakers want tax exemption deadline for export oriented unit (EOUs) to be extended and want infrastructure or priority sector status in the budget on Feb 28.

Buy Dishman Pharma; target of Rs 123: Angel Broking

Angel Broking is bullish on Dishman Pharmaceuticals and has recommended buy rating on the stock with a target of Rs 123 in its February 15, 2011 research report.

Dishman Pharma Dec qtr PAT seen down 47% at Rs 17cr: Karvy

Karvy Stock Broking has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Dishman Pharmaceuticals December quarter sales are expected to go up by 5.3% at Rs 235.3 crore, Year-on-Year, (YoY) basis.